DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach.

IF 3.5 2区医学 Q2 ONCOLOGY Cancer Imaging Pub Date : 2024-07-11 DOI:10.1186/s40644-024-00740-5

Bastien Jamet, Hatem Necib, Thomas Carlier, Eric Frampas, Juliette Bazin, Paul-Henri Desfontis, Aurélien Monnet, Caroline Bodet-Milin, Philippe Moreau, Cyrille Touzeau, Francoise Kraeber-Bodere

{"title":"DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach.","authors":"Bastien Jamet, Hatem Necib, Thomas Carlier, Eric Frampas, Juliette Bazin, Paul-Henri Desfontis, Aurélien Monnet, Caroline Bodet-Milin, Philippe Moreau, Cyrille Touzeau, Francoise Kraeber-Bodere","doi":"10.1186/s40644-024-00740-5","DOIUrl":null,"url":null,"abstract":"Background: Dynamic contrast-enhanced-MRI (DCE-MRI) is able to study bone marrow angiogenesis in patients with multiple myeloma (MM) and asymptomatic precursor diseases but its role in the management of MM has not yet been established. The aims of this prospective study was to compare DCE-MRI-based parameters between all monoclonal plasma cell disease stages in order to find out discriminatory parameters and to seek correlations with other diffusion-weighted MRI and positron emission tomography (PET)-based biomarkers in a hybrid simultaneous whole-body-2-[18F]fluorodeoxyglucose (FDG)-PET/MRI (WB-2-[18F]FDG-PET/MRI) imaging approach.Methods: Patients with newly diagnosed Monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) or symptomatic MM according to international myeloma working group and underwent WB-2-[18F]FDG-PET/MRI imaging including bone marrow DCE sequences at the Nantes University Hospital were prospectively enrolled in this study before receiving treatment.Results: One hundred and sixty-seven patients (N = 167, mean age: 64 years ± 11 [Standard deviation], 66 males) were considered for the analysis. DCE-MRI-based Peak Enhancement Intensity (PEI), Time to PEI (TPEI) and their maximum intensity time ratio (MITR: PEI/TPEI) values were significantly different between the different monoclonal plasma cell disease stages, PEI values increasing and TPEI values decreasing progressively along the spectrum of plasma cell disorders, from MGUS stage to symptomatic multiple myeloma. PEI values were significantly higher in patients with diffuse bone marrow involvement (either in PET or in MRI images) than in those without diffuse bone marrow involvement, unlike TPEI values. PEI and TPEI values were not significantly different between patients with or without focal bone lesions.Conclusion: Different DCE-MRI-based parameters (PEI, TPEI, MITR) could significantly differentiate all monoclonal plasma cell disease stages and complemented conventional MRI and PET-based biomarkers.","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"93"},"PeriodicalIF":3.5000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11241781/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40644-024-00740-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Dynamic contrast-enhanced-MRI (DCE-MRI) is able to study bone marrow angiogenesis in patients with multiple myeloma (MM) and asymptomatic precursor diseases but its role in the management of MM has not yet been established. The aims of this prospective study was to compare DCE-MRI-based parameters between all monoclonal plasma cell disease stages in order to find out discriminatory parameters and to seek correlations with other diffusion-weighted MRI and positron emission tomography (PET)-based biomarkers in a hybrid simultaneous whole-body-2-[18F]fluorodeoxyglucose (FDG)-PET/MRI (WB-2-[18F]FDG-PET/MRI) imaging approach.

Methods: Patients with newly diagnosed Monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) or symptomatic MM according to international myeloma working group and underwent WB-2-[18F]FDG-PET/MRI imaging including bone marrow DCE sequences at the Nantes University Hospital were prospectively enrolled in this study before receiving treatment.

Results: One hundred and sixty-seven patients (N = 167, mean age: 64 years ± 11 [Standard deviation], 66 males) were considered for the analysis. DCE-MRI-based Peak Enhancement Intensity (PEI), Time to PEI (TPEI) and their maximum intensity time ratio (MITR: PEI/TPEI) values were significantly different between the different monoclonal plasma cell disease stages, PEI values increasing and TPEI values decreasing progressively along the spectrum of plasma cell disorders, from MGUS stage to symptomatic multiple myeloma. PEI values were significantly higher in patients with diffuse bone marrow involvement (either in PET or in MRI images) than in those without diffuse bone marrow involvement, unlike TPEI values. PEI and TPEI values were not significantly different between patients with or without focal bone lesions.

Conclusion: Different DCE-MRI-based parameters (PEI, TPEI, MITR) could significantly differentiate all monoclonal plasma cell disease stages and complemented conventional MRI and PET-based biomarkers.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在全身-2-[18F]FDG-PET/MRI混合同步成像方法中，DCE-MRI可区分单克隆浆细胞疾病的所有分期，并与基于弥散加权MRI/PET的生物标记物相关。

背景：动态对比增强磁共振成像（DCE-MRI）能够研究多发性骨髓瘤（MM）患者和无症状前驱疾病患者的骨髓血管生成，但其在MM治疗中的作用尚未确定。这项前瞻性研究的目的是在全身-2-[18F]氟脱氧葡萄糖（FDG）-PET/MRI（WB-2-[18F]FDG-PET/MRI）混合同步成像方法中，比较所有单克隆浆细胞疾病分期之间基于 DCE-MRI 的参数，以找出鉴别参数，并寻求与其他弥散加权 MRI 和基于正电子发射断层扫描（PET）的生物标记物的相关性：方法：根据国际骨髓瘤工作组的标准，对新诊断为意义未定的单克隆丙种球蛋白病（MGUS）、烟雾型多发性骨髓瘤（SMM）或无症状MM，并在接受治疗前在南特大学医院接受了包括骨髓DCE序列在内的WB-2-[18F]FDG-PET/MRI成像的患者进行前瞻性登记：167 名患者（N = 167，平均年龄：64 岁 ± 11 [标准差]，66 名男性）被纳入分析范围。基于 DCE-MRI 的峰值增强强度（PEI）、PEI 时间（TPEI）及其最大强度时间比（MITR：PEI/TPEI）值在不同单克隆浆细胞疾病分期之间存在显著差异，从 MGUS 期到有症状的多发性骨髓瘤，PEI 值在浆细胞疾病谱中逐渐增加，TPEI 值逐渐减少。与 TPEI 值不同的是，有弥漫性骨髓受累（PET 或 MRI 图像）的患者 PEI 值明显高于无弥漫性骨髓受累的患者。PEI和TPEI值在有或无局灶性骨病变的患者之间无明显差异：结论：基于DCE-MRI的不同参数（PEI、TPEI、MITR）可显著区分单克隆浆细胞疾病的所有分期，是对传统MRI和PET生物标志物的补充。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Imaging ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

7.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology. The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Topics of interest include: Breast Imaging Chest Complications of treatment Ear, Nose & Throat Gastrointestinal Hepatobiliary & Pancreatic Imaging biomarkers Interventional Lymphoma Measurement of tumour response Molecular functional imaging Musculoskeletal Neuro oncology Nuclear Medicine Paediatric.